Development of radicicol analogues

Current Cancer Drug Targets

Volumn 3, Issue 5, 2003, Pages 359-369

  Soga, Shiro ^a   Shiotsu, Yukimasa ^a   Akinaga, Shiro ^a   Sharma, Sreenath V ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 O [2 (2 PYRROLIDONYL)ETHYL]RADICILOL; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMATINIB; KF 25706; KF 29163; KF 58332; KF 58333; MACROLIDE; OXIME DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RADICICOL; RADICICOL DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASSAY; BINDING SITE; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COLON CARCINOMA; DRUG BINDING; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; FUNGUS; HUMAN; MAMMAL CELL; MODEL; NEOPLASM; NONHUMAN; ONCOGENE K RAS; ONCOGENE SRC; PROTEIN DEPLETION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR; XENOGRAFT; YEAST;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; GENES, ERBB-2; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTONES; MACROLIDES; MOLECULAR CHAPERONES; NEOPLASMS;

EID: 0141485333     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009033481859     Document Type: Review

References (50)

1. Soga, S.; Kozawa, T.; Narumi, H.; Akinaga, S.; Irie, K.; Matsumoto, K.; Sharma, S.; Nakano, H.; Mizukami, T.; Hara, M. Radicicol Leads to Selective Deletion of Raf Kinase and Disrupts K-Ras-Activated Aberrant Signaling Pathway. J. Biol. Chem. 1998, 273, 822-828.
2. Sharma, S. V.; Oneyama, C.; Yamashita, Y.; Nakano, H.; Sugawara, K.; Hamada, M.; Kosaka, N.; Tamaoki, T. UCS15A, a Non-kinase Inhibitor of Src Signal Transduction. Oncogene 2001, 20, 2068-2079.
3. Zhao, J. F.; Nakano, H.; Sharma, S. V. Suppression of RAS and MOS Transformation by Radicicol. Oncogene 1995, 11, 161-173.
4. Kwon, H. J.; Yoshida, M.; Nagaoka, R.; Obinata, T.; Beppu, T.; Horinouti, S. Suppression of Morphological Transformation by Radicicol is Accompanied by Enhanced Gelsolin Expression. Oncogene 1997, 15, 2625-2631.
5. Kwon, H. J.; Yoshida, M.; Horinouchi, S.; Beppu, T. Radicicol, an Agent Inducing the Reversal of Transformed Phenotypes of Src-transformed Fibroblasts. Biosci. Biotechnol. Biochem. 1992, 56, 538-539.
6. Kwon, H. J.; Yoshida, M.; Fukui, Y.; Horinouchi, S.; Beppu T. Potent and Specific Inhibitor of p60v-src Protein Kinase Both in Vivo and in Vitro by Radicicol. Cancer Res. 1992, 52, 6926-6930.
7. Kwon, H. J.; Yoshida, M.; Muroya, K.; Hattori, S.; Nishida, E.; Fukui, Y.; Beppu, T.; Horinouchi, S. Morphology of Ras-Transformed Cells Becomes Apparently Normal Again with Tyrosine Kinase Inhibitors without a Decrease in the Ras-GTP Complex. J. Biochem (Tokyo) 1995, 118, 221-228.
8. Soga, S.; Neckers, L. M.; Schulte, T. W.; Shiotsu, Y.; Akasaka, K.; Narumi, H.; Agatsuma, T.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Akinaga, S. KF25706, a Novel Oxime Derivative of Radicicol, Exhibits in Vivo Antitumor Activity via Selective Depletion of Hsp90 Binding Signaling Molecules. Cancer Res. 1999, 59, 2931-2938.
9. Witesell, L.; Mimnaugh, E. G.;. De Costa, B.; Myers, C. E.; Neckers, L. M. Inhibition of Heat Shock Protein HSP90-pp60v-src Heteroprotein Complex Formation by Benzoquinone Ansamycins: Essential Role for Stress Proteins in Oncogenic Transformation. Proc. Natl. Acad. Sci. USA. 1994, 91, 8324-8328.
10. Schulte, T. W.; Blagosklonny, M. V.; Romanova, L.; Mushinski, J. F.; Monia, B. P.; Johnstan, J. F.; Nguyen, P.; Trepel, J.; Neckers, L. M. Destabilization of Raf-1 by Geldanamycin Leads to Disruption of the Raf-1-MEK-Mitogen-Activated Protein Kinase Signalling Pathway. Mol. Cell. Biol. 1996, 16, 5839-5845.
11. Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hart, F. U.; Pavletich, N. P. Crystal Structure of an Hsp90-Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent. Cell 1997, 89, 239-250.
12. Schulte, T. W.; Akinaga, S.; Soga, S.; Sullivan. W.; Stensgard, B.; Toft, D.; Neckers, L. M. The Antibiotic Radicicol Binds to the N-terminal Domain of HSP90 and Shares Important Biologic Activities with Geldanamycin. Cell Stress & Chaperones, 1998, 3, 100-108.
13. Sharma, S. V.; Agatsuma, T.; Nakano, H. Targeting of the protein chaperone, HSP90, by the Transformation Suppressing Agent, Radicicol. Oncogene 1998,16, 2639-2645.
14. Schulte, T. W.; Akinaga, S.; Murakata, T.; Agatsuma, T.; Sugimoto, S.; Nakano, H.; Lee, Y. S.; Simen, B. B.; Argon, Y.; Felts, S.; Toft, D. O.; Neckers, L. M.; Sharma, S. V. Interaction of Radicicol with Members of the Heat Shock Protein 90 Family of Molecular Chaperones. Mol. Endocrinol. 1999, 13, 1435-1448.
15. Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural Basis for Inhibition of the Hsp90 Molecular Chaperone by the Antitumor Antibiotics Radicicol and Geldanamycin. J. Med. Chem. 1999, 42, 260-266.
16. Agatsuma, T.; Ogawa, H.; Akasaka, K.; Asai, A.; Yamashita, Y.; Mizukami, T.; Akinaga, S.; Saitoh, Y. Halohydrin and Oxime Derivatives of Radicicol: Synthesis and Antitumor Activities. Bioorg. Med. Chem. 2002, 10, 3445
17. Soga, S.; Sharma, S. V.; Shiotsu, Y.; Shimizu, M.; Tahara, H.; Yamaguchi, K.; Ikuina, Y.; Murakata, C.; Tamaoki, T.; Kurebayashi, J.; Schulte, T. W.; Neckers, L. M.; Akinaga, S. Stereospecific Antitumor Activity of Radicicol Oxime Derivatives. Cancer Chemother. Pharmacol. 2001, 48, 435-445.
18. Munster, P. N.; Marchion, D. C.; Basso, A. D.; Rosen, N. Degradation of HER2 by Ansamycins Induces Growth Arrest and Apoptosis in Cells with HER2 Overexpression via a HER3, Phosphatidylinositol 3′-Kinase-AKT-Dependent Pathway. Cancer Res. 2002, 62, 3132-3137.
19. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human Breast Cancer: Correlation Of Relapse And Survival with Amplification of the HER-2/neu Oncogene. Science. 1987, 235, 177-182.
20. Vivanco, I.; Sawyers C. L. The Phosphatidylinositol 3-Kinase AKT Pathway in Human Cancer. Nat. Rev. Cancer. 2002, 2, 489-501.
21. Fujita, N.; Sato, S.; Ishida, A.; Tsuruo, T. Involvement of Hsp90 in Signaling and Stability of 3-Phosphoinositide-Dependent Kinase-1. J. Biol. Chem. 2002, 277, 10346-10353.
22. Yu, D.; Liu, B.; Tan, M.; Li, J.; Wang, S. S.; Hung, M. C. Overexpression of c-erbB-2/neu in Breast Cancer Cells Confers Increased Resistance to Taxol via Mdr-1-Independent Mechanisms. Oncogene 1996, 13, 1359-1365.
23. Kurebayashi, J.; Otsuki, T.; Kurosumi, M.; Soga, S.; Akinaga, S.; Sonoo, H. A Radicicol Derivative, KF58333, Inhibits Expression of Hypoxia-Inducible Factor-1alpha and Vascular Endothelial Growth Factor, Angiogenesis and Growth of Human Breast Cancer Xenografts. Jpn. J. Cancer Res. 2001, 92, 1342-1351.
24. Minet, E.; Mottet, D.; Michel, G.; Roland, I; Raes, M.; Remacle, J., Michiels, C. Hypoxia-induced Activation of HIF-1: Role of HIF-1 alpha-Hsp90 Interaction. FEBS Lett. 1999, 460, 251-256.
25. Rowley, J. D. Letter: A New Consistent Chromosomal Abnormality In Chronic Myelogenous Leukaemia Identified by Quinacrine Fluorescence and Giemsa Staining. Nature 1973, 243, 290-293
26. Bartram, C. R.; de Klein, A.; Hajemeijer, A.; van Agthoven, T.; Geurts van Kessel, A.; Bootsma, D.; Grosveld, G.; Ferguson-Smith, M. A.; Davies, T.; Stone, M.; Heisterkamp, N.; Stephenson, J. R.; Groffen, J. Translocation of c-abl Oncogene Correlates with the Presence of a Philadelphia Chromosome in Chronic Myelocytic Leukaemia. Nature 1983, 306, 277-280.
27. Groffen, J.; Stephenson, J. R.; Heisterkamp, N.; de Klein, A.; Bartram, C. R.; Grosveld, G. Philadelphia Chromosomal Breakpoints Are Clustered Within a Limited Region, Bcr, on Chromosome 22. Cell 1984, 36, 93-99.
28. Clark, S. S.; Mclaughlin, J.; Timmons, M., Pendergast, A. M.; Ben-Neriah, Y.; Dow, L. W.; Crist, W.; Rovera, G.; Smith, S. D.; Witte, O. N. Expression of a Distinctive BCR-ABL Oncogene in Ph1-Positive Lymphocyte Leukemia. Science 1988, 239, 775-777.
29. Kurzrock, R.; Gutterman, J. U.; Talpas, M. The Molecular Genetics of Philadelphia Chromosome-Positive Leukemia. New Engl. J. Med. 1989, 319, 990-998.
30. O'Dwyer, M. E.; Druker, B. J. Chronic Myelogenous Leukaemia New Therapeutic Principles [Review]. J. Intern. Med. 2001, 250, 3-9.
31. Honma, Y.; Okabe-Kado, J.; Hozumi, M.; Uehara, Y.; Mizuno, S. Induction of Erythroid Differentiation of K562 Human Leukemic Cells by Herbimycin A, an Inhibitor of Tyrosine Kinase Activity. Cancer Res. 1989, 49, 331-334.
32. Fukazawa, H.; Li, P. M.; Yamamoto, C.; Murakami, Y.; Mizuno, S.; Uehara, Y. Specific Inhibitor of Cytoplasmic Protein Tyrosine Kinases by Herbimycin A in Vitro. Biochem. Pharmacol. 1991, 42, 1661-1671.
33. Okabe, M.; Uehara, Y.; Noshima, T.; Itaya, T.; Kunieda, Y.; Kurosawa, M. In Vivo Anti-Tumor Activity of Herbimycin A, a Tyrosine Kinase Inhibitor, Targeted against Bcr-Abl Oncoprotein in Mice Bearing Bcr-Abl Transfected Cells. Leukemia Res. 1994, 18, 867-873.
34. Shiotsu, Y.; Leonard, M.; Neckers, L.; Wortman, I.; Won, G, A.; Schulte, T. W.; Soga, S.; Murakata C.; Tamaoki, T.; Akinaga, S. Novel Oxime Derivatives of Radicicol Induce Erythroid Differentiation Associated with Preferential G1 Phase Accumulation Against Chronic Myelogenous Leukemia Cells through Destabilization of Bcr-Abl with Hsp90 Complex. Blood. 2000, 96, 2288-2291
35. Shiotsu, Y, Soga, S.; Akinaga, S. HSP90 Anagonist Destabilized Bcr-Abl/HSP90 Chaperone Complex. Leukemia Lymphoma 2002, 43, 961-968.
36. Kurzrock, R.; Shtalrid, M.; Romeo, P. Kloetzer, W. S.; Talpas, M.; Trujillo, J. M.; Blick, M.; Beran, M.; Gutterman, J. U. A Novel Abl Protein Product In Philadelphia-Positive Acute Lymphoblastic Leukemia. Nature 1987, 325, 631-635.
37. Afar, D. E.; Goga, A.; McLaughlin, J.; Witte, O. N.; Sawyers, C. L. Differential Complementation of Bcr-Abl Point Mutants with c-Myc. Science 1994, 264, 424-426.
38. Okuda, K.; D'Andrea, A.; Etten, R. A.; Griffin, J. D. A Chimeric Receptor/Oncogene that Can Be Regulated by A Ligand in Vitro and in Vivo. J. Clin. Invest. 1997, 100, 1708-1715.
39. Daley, G. Q.; Baltimore, D. Transformation of an Interleukin 3-Dependent Hematopoietic Cell Line by the Chronic Myelogenous Leukemia-Specific p210bcr/ abl Protein. Proc. Natl. Acad. Sci. USA. 1992, 85, 9312-9316.
40. Skorski, T.; Kanakaraj, P.; Nieborowska-Skorska, M.; Ratajczak, M. Z.; Wen, S. C.; Zon, G.; Gewirtz, A. M.; Perussia, B.; Calabretta, B. Phosphatidylinositol-3 Kinase Activity is Regulated by BCR/ABL And is Required for the Growth of Philadelphia Chromosome-Positive Cells. Blood 1995, 86, 726-736.
41. Marais, R.; Light, Y.; Paterson, H. F.; Marshall, C. J. Ras Recruits Raf-1 to the Plasma Membrane for Activation by Tyrosine Phosphorylation. EMBO J. 1995, 14, 3136-3145.
42. Frank, D. A.; Varticovski, L. Bcr/Abl leads to the Constitutive Activation of Stat Proteins and Shares an Epitope with Tyrosine Phosphorylated Stats. Leukemia 1996, 10, 1724-1730.
43. Skorski, T.; Bellacosa, A.; Nieborowska-Skorska, M.; Majewski, M.; Martinez, R.; Choi, J. K.; Trotta, R.; Wlodarski, P.; Perrotti, D.; Chan, T. O. ; Wasik, M. A.; Tsichlis, P. N.; Calabretta, B. Transformation of Hematopoietic Cells by BCR/ABL Requires Activation of a PI-3k/Akt-Dependent Pathway. EMBO J. 1997, 16, 6151-6161.
44. Druker, B. J.; Tamura, S.; Buchdunger, E. Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a Selective inhibitor of the ABL tyrosine kinase on the growth of bcr-abl positive cells. Nature Med. 1996, 2, 561-566.
45. Deininger, M.; Goldman J. M.; Lydon N. B.; Melo, J. V. The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL Positive Cells. Blood 1997, 90, 3691-3698.
46. Druker, J. B.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. Efficacy and Safety of a Specific Inhibitor Of The Bcr-Abl Tyrosine Kinase in Chronic Myeloid Leukemia. New Engl. J. Med. 2001, 344, 1031-1037.
47. Sawyers, C. L.; Gishizky, M. L.; Quan, S.; Golde, D. W.; Witte, O. N. Propagation of Human Blastic Myeloid Leukemias in the SCID mouse. Blood. 1992, 79, 2089-2098.
48. Mauro, M.; O'Dwyer, M.; Henrich, M. C.; Drucker, B. ST1571: A Paradigm of New Agents for Cancer Therapeutics. J. Clin. Oncol. 2002, 20, 325-334.
49. Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P. N.; Sawyers, C. L. Clinical Resistance to ST1571 Cancer Therapy Caused by Bcr-Abl Gene Mutation or Amplification. Science 2001, 293, 876-880.
50. Gorre, M. E.; Ellwood, K.; Chiosis, G.; Rpsen, N.; Sawyers, C. Bcr-Abl Point Mutation Isolated from Patients with Imatinib-Resistant Chronic Myeloid Leukemia Remain Sensitive to Inhibitors of the Bcr-Abl Chaperone Heat Shock Protein 90. Blood 2002, 100, 3041-3044.